GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Fair Value & Analysis
Healthcare · IN · Market cap ₹409B
Fair value as of: Aug 13, 2026
From 25 valuation models · updated 3 days ago
Share price +8.3% over the past month.
A strong business, but screening 64% overvalued on our models.
What matters now
- A high-quality business (quality 80/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (₹1,414). The favourable scenario is already priced in.
- A fairly wide model range (₹675.27 to ₹1,414) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹1,139 – ₹3,380 · fair‑value band ₹675.27 – ₹1,414 · the ₹2,689 price screens above the ₹960.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) currently trades at ₹2,689, while our model-based Fair Value estimate is ₹960.13, implying the stock looks roughly 64.3% overvalued today. The Quality Score stands at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, GlaxoSmithKline Pharmaceuticals Limited generated revenue of ₹38.2B at a net margin of 27.1%. Revenue grew 2.1% year over year. It earns a return on equity of 49.1%. The balance sheet holds a net cash position of ₹10.7B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹675.27 (bear case) to ₹1,414 (bull case); at ₹2,689, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 29% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -64%, GLAXO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (₹1,088) versus Asset-Based (₹89.68). Highest evidence: Growth DCF (80).
Notify me when GLAXO reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 78 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix.
Full company description
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹38.2B in FY2026 versus ₹32.6B in FY2022, a compound +4.0%/yr. Reported net income was ₹10.4B in FY2026, compounding −11.6%/yr from FY2022.
of which total revenue +3.3 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
GLAXO screens 64% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,220 | $389.47 | -68% |
| Johnson & Johnson, JNJ | $260.86 | $169.04 | -35% |
| AbbVie Inc ABBV | $248.76 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €240.14 | -39% |
| Merck & Co MRK | €115.42 | €118.21 | +2% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| AstraZeneca PLC AZN | $158.50 | $127.32 | -20% |
| Novo Nordisk A/S NOVOB | kr 299.50 | kr 409.46 | +37% |
| Sanofi SNYN | 770.00 MXN | 1,041 MXN | +35% |
| GSK plc GSKN | 917.00 MXN | 879.08 MXN | -4% |
Compare GlaxoSmithKline Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GlaxoSmithKline Pharmaceuticals Limited (GLAXO) overvalued or undervalued?
What is the fair value of GLAXO?
What is the quality score of GLAXO?
What is the revenue of GlaxoSmithKline Pharmaceuticals Limited (GLAXO)?
What is the net profit margin of GLAXO?
Does GlaxoSmithKline Pharmaceuticals Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GlaxoSmithKline Pharmaceuticals Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.